Abbott Laboratories is spinning off its nutrition business (Similac, Pedialyte) into a separate publicly traded company via a share distribution to existing investors. The unit has ~$8.5B in annual sales and has faced a contamination crisis, shortages, and lawsuits. Abbott also reported Q3 results with softness in heart and diabetes products. Shares fell ~4%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
